Objective: To assess the relationship between infant feeding, triple-antiretroviral prophylaxis and weight from 2 weeks (baseline) to 6 months postpartum among HIV-infected mothers in a mother-to-child transmission (MTCT) of HIV-prevention trial in five sub-Saharan African sites.
Introduction
Weight loss [1, 2] and low BMI [3, 4] among HIV-infected individuals are markers of HIV disease progression and increased risk of mortality. In HIV-infected women, the energy requirements of lactation [5] , combined with the metabolic burden of the infection [6] , have the potential to lead to nutritional depletion, especially in those whose nutritional status is already compromised. Studies assessing weight change among HIV-infected women during lactation are sparse. Two studies reported a positive association between breastfeeding and weight loss [7, 8] , and two reported there to be no association [9, 10] . Inconsistencies in methodology and follow-up time period make these results difficult to compare. Moreover, most studies were conducted before antiretrovirals to prevent mother-to-child transmission (MTCT) of HIV became widely available.
In settings where health authorities have decided to promote breastfeeding and antiretroviral interventions for prevention of MTCT, the WHO now recommends that HIV-infected mothers should exclusively breastfeed their infants for the first 6 months and continue breastfeeding up to 12 months [11] . Antiretroviral prophylaxis should be initiated early in pregnancy and prolonged, at least, as long as the mother breastfeeds [12] . This prevention strategy is expected to substantially reduce the risk of postnatal transmission [13, 14] , and also might improve maternal clinical outcomes and mitigate any lactationassociated weight loss. Indeed, antiretroviral initiation is associated with weight gain in immuno-compromised treatment-naive patients [15, 16] . However, little is known about the effect of antiretroviral prophylaxis (to prevent MTCTof HIV) on postpartum weight change by infant feeding mode among women with an intermediate HIV disease stage.
The present analysis aimed to address this issue using data collected in the Kesho Bora randomized controlled trial (RCT) conducted in sub-Saharan Africa. This trial assessed the efficacy of a triple-antiretroviral prophylaxis to reduce MTCT of HIV among women who did not need antiretrovirals for their own health. A recent publication, addressing HIV disease progression in these women, reported a lower BMI in mothers randomized to the control arm, zidovudine (ZDV) and single-dose nevirapine (sdNVP), compared with those in the tripleantiretroviral arm, at all times postpartum, although differences were statistically significant only at 12 months [17] .
The primary objective of this study was to examine the role of infant feeding on maternal weight change up to 6 months postpartum among HIV-infected women enrolled in the Kesho Bora trial. We aimed to determine whether receiving triple-antiretroviral prophylaxis would modify the relationship between infant feeding and postpartum weight change. We hypothesized that tripleantiretroviral prophylaxis would prevent any significant effects of lactation on postpartum weight loss.
Methods
The Kesho Bora study This is an analysis of data collected as part of the Kesho Bora trial. Full details of the rationale for this study and methods are provided elsewhere [18] . Briefly, the Kesho Bora study included a RCT in HIV-infected pregnant women in five study sites (Bobo-Dioulasso, Burkina Faso; Mombasa and Nairobi, Kenya; Durban and Somkhele, South Africa). Inclusion criteria were pregnancy less than 32 weeks' gestation and CD4 þ cell counts of 200-500 cells/ml. At 28-34 weeks' gestation, women were randomly assigned (1 : 1) to start either perinatal antiretroviral prophylaxis with ZDV and sdNVP or triple-antiretroviral prophylaxis with stratification by study site and intended infant feeding choice. Women allocated to the ZDV/sdNVP group received ZDV twice daily until delivery, ZDV and sdNVP at onset of labour, and 1 week of ZDV and lamivudine (3TC), twice daily postpartum. Women allocated to the triple-antiretroviral prophylaxis (triple-antiretroviral group) received ZDV, 3TC and lopinavir/ritonavir twice daily until cessation of breastfeeding. Triple-antiretroviral prophylaxis was stopped 1 month after delivery for women who chose not to breastfeed.
Women were seen at the study site every 2 weeks from enrollment until 8 weeks after delivery, monthly until 1 year and every 3 months up to 18 or 24 months. All participants were counselled on infant feeding throughout the study as per 2003 WHO guidelines [19] . Women who opted for breastfeeding were supported to exclusively breastfeed and rapidly wean with complete cessation before the infant reached 6 months of age. At each scheduled visit, mothers were provided with nutrition counselling that particularly focused on nutrient requirements related to HIV infection. In Mombasa and South Africa, breastfeeding mothers received food aid which provision modalities varied according to national guidelines.
Socioeconomic and demographic data were collected at enrollment. Anthropometric measurements were collected by trained fieldworkers according to international recommendations [20] . Infant feeding patterns were longitudinally assessed by an adaptation of the WHO infant feeding assessment tool [21] . Blood samples were obtained for CD4 þ cell count monitoring at enrollment, delivery, and 3, 6, 12 and 18 months postpartum.
Ethics clearance for the study was given by the ethics and regulatory committees in Burkina Faso, Kenya and South Study population and definitions for this analysis The study population for this analysis comprised women enrolled in the RCTwho delivered a live born infant, for whom infant feeding was reported at one or more visit and for whom at least one weight measurement between 2 weeks to 6 months postpartum was available. Since few women prolonged breastfeeding into the second half of the first year postpartum [22] , the analysis was restricted to the first 6 months.
Infant feeding mode was first defined as 'replacement feeding' for mothers who gave only replacement feeding from birth and as 'breastfeeding' for mothers who ever breastfed. Secondly, breastfeeding mothers were classified by breastfeeding duration: short ( 3 months) vs. long (>3 months). Thirdly, short-term and long-term breastfeeding mothers were divided by two breastfeeding modalities: full breastfeeding (both exclusive and predominant) practiced during 75% or less of the breastfeeding duration, or during more than 75% of the breastfeeding duration.
BMI was calculated as weight (kg)/height (m) 2 . The BMI at 2 weeks postpartum was used as the baseline for this analysis. If a 2-week weight measurement was not available, the 4 or 6-week measure was used. BMI groups were defined according to standard classification (underweight <18.5, normal !18.5 to <25, overweight !25 to <30 and obese !30).
A socioeconomic score was calculated by multiple correspondence analysis using eight household assets (electricity, refrigerator, radio, television, telephone, source of water, type of toilets and type of fuel). This score was categorized in tertile of increasing economic level.
Statistical analysis
The study outcome was the maternal weight in kilograms. The primary objective was to evaluate the association between infant feeding mode and the study outcome across the first 6 months postpartum. Antiretroviral prophylaxis was examined as an independent risk factor and a potential effect modifier. First, maternal characteristics were compared between infant feeding modes using general linear regression models and chi-square tests.
Maternal weight change between 2 weeks and 3 months postpartum, and between 3 and 6 months postpartum, was compared between infant feeding mode stratified by antiretroviral prophylaxis, using general linear regression models. Then, mixed-effects linear models (MLMs) with an autoregressive covariance structure were used to examine infant feeding (breastfeeding vs. replacement feeding) effects on postpartum weight across all visits. Models included random intercepts for each participant and study site. Analyses were adjusted for baseline BMI to account for the expected dependence of weight change on baseline weight and for antiretroviral prophylaxis as an independent risk factor. We also investigated a number of potential confounders, including variables related to maternal clinical status and sociodemographic and economic conditions.
Formal tests for effect modification over time within the MLMs were conducted using simple interaction terms with infant feeding, antiretroviral prophylaxis and baseline BMI (as a continuous and qualitative variable). Other first and higher-order interactions were tested between antiretroviral prophylaxis, infant feeding, baseline BMI and time. In these models, underweight and normal women were grouped into 'low BMI' (<25), and overweight and obese into 'high BMI' (!25) classes. Secondly, similar MLMs only including ever breastfeeding women were used to assess the association of breastfeeding duration (as continuous and binary variable) and breastfeeding modalities with postpartum weight change. Ultimately, sensitivity analyses were run excluding mothers who died or were lost to follow-up before 6 months postpartum, and excluding mothers with first weight measurement available at 4 and 6 weeks. Differences were considered significant at P less than 0.05. All statistical analyses were performed in SAS (version 9.2, Cary, North Carolina, USA).
Results
Size and characteristics of the study population Between June 2005 and August 2008, 805 women were enrolled in the RCT. Of these, 799 had at least one visit where infant feeding was ascertained and 797 had also at least one weight measured from 2 weeks to 6 months postpartum. Therefore, the study population for this analysis comprised 797 women, of whom 783 had a baseline BMI value available.
Overall, 78% of mothers opted to breastfeed (620 of 797) ( Table 1) . Among these, 28% did so for up to 3 months with a median duration of 1.6 month (interquartile range 0.9-2.2), and 72% for longer than 3 months with a median duration of 5.6 months (interquartile range 4.9-6.1). Only 2% of mothers were underweight at baseline, whereas more than 40% had a BMI at least 25, of whom a quarter were obese. Baseline nutritional status differed significantly by site: mean (AESD) BMI was 22.8 AE 3.2, 23.3 AE 3.4, 24.2 AE 3.8, 26.1 AE 4.2 and 27.4 AE 4.4 in Nairobi, Bobo-Dioulasso, Mombasa, Somkhele and Durban, respectively (P < 0.0001).
Postpartum weight gain by antiretroviral prophylaxis and infant feeding Overall, mothers' weight remained relatively stable between 2 weeks and 6 months postpartum (Fig. 1a) , with the greatest weight change being þ1.5 kg AE 4.9 among replacement-feeding mothers in the tripleantiretroviral group and the lowest being À0.9 kg AE 4.5 among short-term breastfeeding mothers in the ZDV/sdNVP group (Fig. 1b) .
In the triple-antiretroviral group, both short-term and long-term breastfeeding mothers lost weight between 2 weeks and 3 months postpartum (Table 2) . Short-term breastfeeding and replacement-feeding mothers gained weight between 3 and 6 months, whereas long-term breastfeeding mothers started to gain weight later, between 5 and 6 months postpartum (þ0.2 kg AE 1.6) (Fig. 1b) . 
CD4
R cell count increase by antiretroviral prophylaxis and infant feeding Between enrollment and delivery, women in the tripleantiretroviral group had a greater mean CD4 þ cell count increase when compared to those in the ZDV/sdNVP group (þ161 cells/ml AE 164 vs. þ106 cells/ml AE 130, respectively; P < 0.0001).
In the triple-antiretroviral group, long-term breastfeeding mothers had a CD4 þ cell count increase from delivery to 3 months postpartum (all were receiving antiretrovirals during this period) and a slight decrease from 3 to 6 months (some mothers ceased breastfeeding and thus antiretrovirals during this period) ( Table 2) . Mothers who ceased antiretrovirals early in the postpartum period (i.e. short-term breastfeeding and replacement-feeding General linear models were used to test for associations between dependent variables and infant feeding mode. Women with weight data available (or replaced) at 2 weeks and 3 months, then at 3 and 6 months were included in weight change analysis. Women with CD4 þ cell count data available at delivery and 3 months, and at 3 and 6 months were included in CD4 þ cell change analysis.
mothers) had a continuous CD4 þ cell count decrease from delivery to 6 months. Replacement feeding mothers in the ZDV/sdNVP group had the lowest median CD4 þ cell count at enrollment, delivery and 6 months postpartum when compared with their breastfeeding counterparts (P ¼ 0.01 for all time points).
Risk factors associated with postpartum weight change
To identify factors associated with postpartum weight change, we ran a MLM including infant feeding, antiretroviral prophylaxis regimen, baseline BMI and other maternal characteristics as covariates. Interactions were tested, and a four-way interaction between time, infant feeding, antiretroviral prophylaxis and baseline BMI was found to be statistically significant (P ¼ 0.0004), indicating that the relationship between infant feeding and weight change differed by type of prophylaxis and BMI at baseline.
Weight change per month (Table 3 ) was thus estimated in each of the subgroups defined by antiretroviral prophylaxis, infant feeding and baseline BMI. In the tripleantiretroviral group, there was a significant difference in weight gain over time between replacement-feeding and breastfeeding mothers with high BMI [þ0.46 kg/month, 95% confidence interval (CI) 0.17-0.74, P ¼ 0.002]. In contrast, there was no difference between infant feeding groups with low BMI. In the ZDV/sdNVP group, there was no difference in weight gain between replacementfeeding and breastfeeding mothers, in high and low BMI classes. A CD4
þ cell count at enrollment of 350-500 cells/ml remained independently and positively associated with weight gain across all study visits (Table 3) . Similar MLMs were run for assessing the effects of the previous factors on the relationship between breastfeeding duration (short vs. long) and modalities (short vs. long, full breastfeeding 75% or >75% of the time) and postpartum weight. Breastfeeding duration, antiretroviral prophylaxis regimen and baseline BMI group were not significantly associated with weight change, except for short-term breastfeeding by mothers with high BMI in the triple-antiretroviral group who gained weight over time (0.33 kg/month, 95% CI 0.03-0.63, P ¼ 0.03). There was no association between any categories of breastfeeding modalities with postpartum weight change over time.
90
AIDS 2014, Vol 28 No 1 Seven hundred and eighty-three (of 797) women with a baseline BMI value directly available or replaced were included in this analysis. Among these, 4% did not complete 6-month follow-up: 19 moved, nine refused to continue, three died and four were lost to follow-up. Sensitivity analysis were run without mothers who died or were lost to follow-up before 6 months postpartum (n ¼ 7 of 783), and without mothers with first weight measurement available at 4 and 6 weeks (n ¼ 43 of 783). In both models, results remained unchanged. Sensitivity analyses were run excluding mothers who died or were lost to follow-up before 6 months postpartum (n ¼ 7 of 783), and excluding mothers with first weight measurement available at 4 and 6 weeks (n ¼ 43 of 783). In both models, results remained unchanged.
Discussion
The objective of this study was to investigate the association between infant feeding mode and postpartum weight change of HIV-infected mothers participating in a MTCT prevention trial, with the hypothesis that a tripleantiretroviral prophylaxis would reduce weight loss among breastfeeding women. Contrary to our expectations, weight trajectories were remarkably stable among breastfeeding mothers up to 6 months postpartum, irrespective of their antiretroviral prophylaxis regimen and baseline nutritional status. Triple-antiretroviral prophylaxis was significantly associated with weight gain among mothers with a BMI at least 25 who formula-fed from birth or who ceased breastfeeding. Thus, tripleantiretroviral prophylaxis may enhance postpartum weight gain in overweight mothers in the absence of breastfeeding.
A few studies have addressed postpartum weight change in breastfeeding HIV-infected mothers. In a RCT in Kenya, formula-feeding mothers lost no weight from the earliest postpartum visit up to 5-9 months, whereas breastfeeding mothers lost 0.17 kg/month (P ¼ 0.03) [23] . A cohort study reported a slightly more rapid decline in BMI in breastfeeding than in formula-feeding Kenyan mothers from 1 to 24 months postpartum (P ¼ 0.4) [7] . Conversely, in Zambia, the average weight gain between 4 and 24 months postpartum was 1.1 kg in HIV-infected mothers who breastfed for a median duration of 16 months [9] . In Tanzania, there was no difference in the risk of 10% weight loss after 6 months postpartum between breastfeeding and formula-feeding mothers [10] . All these studies were conducted before widespread access to antiretroviral prophylaxis in a context of prolonged breastfeeding. The Breastfeeding, Antiretrovirals, and Nutrition (BAN) Study, conducted in Malawi, randomized HIV-infected mothers and their infants at delivery according to a two-arm (with and without nutrient supplement)-by-three-arm (maternal triple-antiretroviral prophylaxis, infant-NVP prophylaxis or neither) factorial design [24] . Breastfeeding mothers in the triple-antiretroviral arms lost significantly more weight (À2.93 kg) from 0 to 28 weeks than did those not provided with antiretroviral prophylaxis (À1.90 kg). However, triple-antiretroviral prophylaxis was initiated at delivery or even later in some mothers (up to 21 weeks postpartum) so that exposure to drugs was shorter than in our study.
Our findings are thus consistent with these African studies which reported no detrimental effects of breastfeeding on HIV-infected women's nutritional status, and suggest that metabolic adaptations to protect energy reserves during lactation [25, 26] also occur in HIV-infected women. We cannot exclude that food support provided to breastfeeding mothers in South Africa and Mombasa has mitigated weight loss. However, targeted food provision programmes do not reach all women and generally suffer from family leakages [27] . Moreover, this hypothesis is not strongly supported by the BAN study which reported a significant but modest difference in weight change from delivery to 28 weeks postpartum between nutrient supplement groups of þ0.76 kg in mothers receiving triple-antiretroviral prophylaxis and þ0.53 kg in those not provided with antiretroviral prophylaxis [24] .
As a main result of this study, the triple-antiretroviral prophylaxis combined with high BMI at baseline was associated with increased weight gain in the absence of breastfeeding or after weaning. First, most women on the triple-antiretroviral prophylaxis had a significantly greater increase in CD4 þ cell count during pregnancy than those in the ZDV/sdNVP group. During the postpartum period, continuous CD4 þ cell count increase was limited to the period of use of antiretroviral prophylaxis, although mothers who received the triple-antiretroviral prophylaxis still had higher median CD4 þ cell count than those in the ZDV/sdNVP group at 18 months postpartum [17] . Thus, a few months of triple-antiretroviral prophylaxis allowed lasting improvements in immunological status among these antiretroviral-naive women and could be an indirect factor of weight gain, even after antiretroviral cessation. Second, there were very few cases of maternal malnutrition at baseline, whereas the prevalence of overweight and obesity was substantial, particularly in Mombasa and South African sites. Intermediate analyses showed a strong interaction between BMI at baseline and postpartum weight change over time. Finally, only replacement-feeding mothers in the ZDV/sdNVP group with BMI below 25 at baseline were at risk of losing weight during the study period. We hypothesize that avoidance of breastfeeding would have been partly motivated by a deterioration of health among some of them at the time of delivery.
To the best of our knowledge, our study is the first to address the association of triple-antiretroviral prophylaxis with postpartum weight change in well nourished HIVinfected mothers. African women [28] and particularly those living with HIV [29, 30] often show a preference for body images which represent greater body weight and a desire to gain weight. Recent research has shown that overweight and obesity are now prevalent among HIV-infected people in developing countries [30, 31] . Moreover, previous studies reported that excessive weight at initiation of antiretroviral prophylaxis could be associated with faster weight gain and progression towards overweight and obesity [31, 32] . Thus, we might expect that the initiation of lifelong antiretroviral prophylaxis, in similar population of well nourished women at intermediate-disease stage, might promote sustained and even greater weight gain over time than that observed in the present study.
The implementation of option Bþ of the WHO 2012 recommendations, which proposes continuing antiretroviral prophylaxis for life [33] , is likely to benefit many mothers' health and nutritional status. However, specific attention should be focused on overweight and obese women initiating lifelong antiretroviral prophylaxis in terms of clinical and biological monitoring. Nutritional counselling guidelines, which currently mainly focus on breastfeeding and HIV infectionassociated nutrient requirements, should also be updated for the inclusion of advice on healthy diets and physical activity.
Lack of availability of pre-pregnancy weight data may have biased the interpretation of postpartum weight change. However, it is extremely difficult to obtain such data in sub-Saharan Africa and, in the absence of differences in maternal weight between antiretroviral prophylaxis arms at enrollment, it is unlikely that results would have differed if we had been able to adjust for prepregnancy nutritional status. A further limitation of the study is that data on subsequent pregnancies were not available in the Kesho Bora database. Limiting the analysis to the first 6 months postpartum makes it unlikely that weight data of pregnant mothers would have been included. Finally, our results, even if based on three very different sub-Saharan countries, can probably not be extended to all HIV-infected women in Africa. Women enrolled in the RCT may have been healthier than other HIV-infected mothers in the same settings due to highquality care and psychosocial support provided during the study. Also, most of the participants were living in urban or peri-urban settings. Further studies addressing the effect of antiretroviral prophylaxis and lifelong antiretrovirals on weight in women at intermediate stages of HIV infection are needed.
In conclusion, our results indicate that full breastfeeding up to 6 months postpartum is not detrimental to the nutritional status of well nourished, HIV-infected mothers with intermediate CD4 þ cell counts. Antiretroviral initiation together with being overweight or obese may be an important predictor for weight gain in replacement-feeding mothers or after breastfeeding cessation. These findings are highly relevant for public health as a growing number of HIV-infected pregnant women will be provided with lifelong antiretrovirals in settings where overweight and obesity become more prevalent each year.
